The world’s leading insulin supplier, Novo Nordisk, turns in a superb performance in the first six months of 2015. Sales revenues increased, two IIIa trials were successfully completed and two new treatments are now available on the huge diabetes market of the US.
We visited Denmark for our last Labiotech tour. We knew Novo was important, but not as important as we saw. Novo was literally everywhere, financing basic research, biotech start ups and later-stage ventures. It even represents the most valuable Danish publicly listed company. (Our Denmark documentary will be published in September, but before, you can have a look at the teaser!)
Novo Nordisk possesses one of the broadest portfolios for the treatment of diabetes. Since its foundation in 1923, the Danish company hasn’t stopped growing, and 2015 is no exception. In the first half of the year, the company’s sales got up by 25% to €7Bn (DKK52.3Bn) and the net profit climbed by 35% to €2.44Bn (DKK18.2Bn). North America and China greatly contributed to this rise.